In this study, we firstly demonstrated that NCTD inhibits tumor VM and prolongs host survival in highly aggressive gallbladder cancers probably via blocking the EphA2/FAK/Paxillin signaling pathway, and could serve as a potential anti-VM agent for human highly aggressive gallbladder cancers. Here, PTK2 is linked to neoplasm.